MUHAMAD ALY RIFAI: Open Payments
NPI 1922053388 · EASTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,451 in 210 payments from 15 companies in 2025. Trend: 2023 $3,562 · 2024 $3,078 · 2025 $4,451
Food & beverage: $4,328Education: $123
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $715 |
| Vanda Pharmaceuticals Inc. | 31 | $616 |
| Alkermes, Inc. | 20 | $588 |
| Teva Pharmaceuticals USA, Inc. | 27 | $547 |
| Otsuka America Pharmaceutical, Inc. | 24 | $437 |
| Janssen Pharmaceuticals, Inc | 12 | $259 |
| E.R. Squibb & Sons, L.L.C. | 11 | $220 |
| Braeburn Inc. | 5 | $219 |
| Axsome Therapeutics, Inc. | 5 | $217 |
| Neurocrine BioSciences, Inc. | 9 | $217 |
Products named: VRAYLAR, FANAPT, ARISTADA, AUSTEDO XR, REXULTI, COBENFY, BRIXADI, Auvelity.
Industry payments across PA — which companies pay providers there.
